Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Alain VergnenegreMargaux GeierFlorian GuisierRegine LamyBénédicte CometGwenaelle Le GarffPascal DoHenri JanicotHugues MorelChantal DecroisetteMichel AndreLionel FalcheroNicolas PaleironIsabelle Monnetnull nullPublished in: Cancer medicine (2019)
In the real-life setting, NSCLC RP on ICI remains a challenge. New descriptive and analytic studies are needed to identify factors predictive of RP.